振德医疗(603301) - 2025 Q3 - 季度财报

Financial Performance - Total revenue for the third quarter was ¥1,084,062,685.61, representing a year-on-year increase of 0.10%[4] - Total profit decreased by 49.85% to ¥91,769,976.45 compared to the same period last year[4] - Net profit attributable to shareholders was ¥75,421,982.51, down 48.47% year-on-year[4] - Basic and diluted earnings per share both decreased by 49.09% to ¥0.28[5] - The weighted average return on equity decreased by 1.33 percentage points to 1.33%[5] - Net profit for the first three quarters of 2025 was ¥210,543,772.08, down from ¥317,474,354.86 in 2024, reflecting a decrease of approximately 33.6%[22] - Basic earnings per share for the first three quarters of 2025 were ¥0.76, down from ¥1.15 in the same period of 2024, representing a decline of approximately 33.9%[22] Assets and Liabilities - Total assets increased by 10.92% to ¥8,404,612,469.65 compared to the end of the previous year[5] - The company's total assets increased to ¥8,404,612,469.65 in 2025 from ¥7,576,854,384.35 in 2024, marking a growth of about 10.9%[17] - Total liabilities rose to ¥2,419,250,212.67 in 2025, compared to ¥1,680,456,463.01 in 2024, an increase of approximately 43.9%[17] - The company's total non-current assets amounted to ¥5,486,517,555.15 in 2025, up from ¥4,927,035,342.48 in 2024, indicating a growth of about 11.4%[17] Cash Flow - Net cash flow from operating activities for the year-to-date was ¥262,639,201.32, an increase of 64.65%[4][10] - Operating cash flow for the first three quarters of 2025 reached ¥262,639,201.32, a 64.5% increase from ¥159,518,116.70 in the same period of 2024[25] - Total cash inflow from operating activities was ¥3,695,211,630.06, compared to ¥3,382,595,024.60 in 2024, reflecting an increase of 9.2%[25] - Cash outflow for purchasing goods and services was ¥2,047,025,563.82, up from ¥1,991,557,515.14 in 2024, indicating a rise of 2.8%[25] - Cash inflow from financing activities increased to ¥1,536,500,000.00, compared to ¥1,419,260,000.00 in the previous year, marking an 8.3% growth[26] - Net cash flow from financing activities was ¥619,687,236.34, significantly higher than ¥234,402,342.05 in 2024, representing a 164.5% increase[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,562[12] - Zhejiang Zhendé Holdings Co., Ltd. holds 49.82% of the shares, with 132,739,480 shares pledged[12] - The company has a total of 13,322,560 shares (5.00% of total shares) to be transferred at a price of RMB 26.74 per share, totaling RMB 356,245,254.40[14] - The company has no significant changes in the top ten shareholders participating in margin financing and securities lending[13] - The company’s major shareholders include both corporate and individual entities, with no known related party transactions among them[13] Inventory and Receivables - Accounts receivable stand at RMB 693,903,555.27, down from RMB 756,695,009.51[15] - Inventory is reported at RMB 762,281,766.54, slightly decreased from RMB 770,721,810.80[15] - Total current assets amount to RMB 2,918,094,914.50, compared to RMB 2,649,819,041.87 in the previous period[15] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥99,515,975.55, slightly up from ¥98,872,971.89 in 2024, reflecting a marginal increase of about 0.6%[21] Non-Recurring Items - Non-recurring gains and losses for the current period totaled ¥10,587,609.54[8] - The decrease in total profit and net profit was primarily due to asset disposal gains from the previous year, which were not repeated this year[9][10]